Primary Care ERectile Function Outcome Registry for Men

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07356609

Acronym

PERFORM

Enrollment

255

Registered

2026-01-21

Start date

2026-02-06

Completion date

2027-05-31

Last updated

2026-01-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Erectile Dysfunction

Keywords

Erectile dysfunction, male reproductive health, male sexual health

Brief summary

The PERFORM registry is a structured, real-world data platform designed to systematically capture patient characteristics, disease severity and treatment patterns of Erectile Dysfunction (ED) across Pakistan. By reflecting routine clinical practice, an ED registry provides valuable insights into the disease epidemiology, unmet needs, and variations in care across populations. It supports evidence-based decision-making, helps identifying early predictors, and inform guideline development, health policy, and personalized management strategies in male sexual health.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

MALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Adult male above 18 years of age 2. Married 3. Diabetic 4. Patient reports erectile dysfunction (symptomatic). 5. Patient is eligible to be prescribed sildenafil by treating clinician.

Exclusion criteria

1. If at any other PDE-5 inhibitor (sildenafil, tadalafil, vardenafil, avanafil) 2. Concurrent use of organic nitrates (any form: glyceryl trinitrate, isosorbide mononitrate/dinitrate) - absolute contraindication 3. Recent or unstable cardiovascular disease * Myocardial infarction or stroke in last 3 months * Unstable angina * Uncontrolled arrhythmia or heart failure NYHA III-IV * Resting hypotension (SBP \< 90 mmHg) or uncontrolled hypertension (SBP \> 180 mmHg) per treating clinician * Known severe hepatic impairment or severe renal impairment on dialysis (if local clinician deems unsafe) * Known hypersensitivity to sildenafil or excipients * Concomitant use of potent CYP3A4 inhibitors (e.g., ritonavir) - unless clinician documents safe plan/dose adjustment

Design outcomes

Primary

Measure	Time frame	Description
Descriptive data of frequency, severity of ED in Pakistan	Baseline	Prevalence
Descriptive data [age, income (derivative of socio-economic class), rural/urban population and occupation]	baseline	Demographics

Secondary

Measure	Time frame	Description
Age of diabetes in ED patients	baseline	Duration of diabetes in ED patients
Duration of ED	baseline	Disease duration

Contacts

CONTACTHussain Abidi

hussain.baqar@nabiqasim.com+923322583236

Outcome results